ReviewFrontiers in oncology2021

UCP2 as a Potential Biomarker for Adjunctive Metabolic Therapies in Tumor Management.

Frederic A Vallejo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.